Clin Appl Thromb Hemost. 2026 Jan-Dec;32:10760296261508934. doi: 10.1177/10760296261508934. Epub 2026 Nov 15.
ABSTRACT
BackgroundDysglycemia is common in patients with atrial fibrillation (AF)-related acute ischemic stroke (AIS), yet the prognostic relevance of acute versus chronic glycemic status in anticoagulated patients remains unclear.MethodsConsecutive patients with AF-related AIS receiving anticoagulation therapy were enrolled. The endpoint was a composite of recurrent ischemic stroke, transient ischemic attack, systemic embolism, moderate-to-severe bleeding, and all-cause mortality. Multivariable Cox proportional hazards models were used to assess associations of fasting plasma glucose (FPG) and glycated hemoglobin A1c (HbA1c) with outcomes. Restricted cubic splines explored potential nonlinear relationships. Patients were categorized by American Diabetes Association HbA1c criteria, and an FPG × HbA1c interaction was tested. Kaplan-Meier analyses illustrated cumulative event rates.ResultsAmong 623 patients, higher baseline FPG was independently associated with the composite outcome at both 90 days (hazard ratio [HR] per 1 mmol/L increase = 1.084, 95% confidence interval [CI]: 1.014-1.160) and 1 year (HR = 1.075, 95% CI: 1.016-1.136). FPG remained significantly associated with adverse outcomes at 90 days (HR = 1.101, 95% CI: 1.018-1.191) and 1 year (HR = 1.087, 95% CI: 1.019-1.159), whereas HbA1c categories showed no significant associations. No significant interaction between FPG and HbA1c was observed. Kaplan-Meier analyses demonstrated no significant differences in cumulative event rates across HbA1c-defined glycemic groups.ConclusionsElevated baseline FPG was independently associated with short- and long-term adverse outcomes in anticoagulated patients with AF-related AIS. Acute-phase glycemia may provide prognostic information complementary to HbA1c, without significant effect modification by chronic glycemic status.
PMID:43034908 | DOI:10.1177/10760296261508934